Skip to content

The Peptide Possibilities Edition | Essential: The Pharmacy Compounding Podcast

Pharmacy Podcast Network

37m
Transcript

Original podcast

Where to listen

Summary

Written by a model from the transcript; not yet reviewed.

The episode explores the complex debate around peptide compounding and the Alliance for Pharmacy Compounding’s proposed guardrails for regulated access. Andrew Cantor leads a discussion with guests Philip Smith and Scott Bruner on the current gray market of unregulated peptides, the risks of low-quality active pharmaceutical ingredients, and the balance between patient access and safety. The speakers argue that a middle ground involving strict ingredient sourcing, patient disclosures, and utilization reporting is essential to prevent harmful overcorrections and protect public health.

  • Compounding pharmacies should source active pharmaceutical ingredients through FDA-registered repackagers and relabelers to ensure proper testing and quality control upstream. 15:55
  • Patient disclosures should accompany compounded peptide prescriptions to clearly communicate that the active ingredients are not yet proven safe or effective by the FDA. 27:41
  • Adverse event reporting for non-monograph products should focus on serious adverse events to avoid data noise from minor issues like injection site redness. 29:00
  • De-identified dispensing data must be paired with adverse event reports to provide the necessary denominator for contextualizing safety signals. 30:43

Chapters

  1. 0:05
    Podcast Introduction and News Teaser

    Hosts open the episode, previewing compounding news and the upcoming deep dive on peptides.

  2. 0:53
    Counterfeit Ozempic Arrests Highlight Counterfeiting Threat

    Federal prosecutors charge Indian nationals for smuggling counterfeit Ozempic, underscoring the risks of unregulated peptide markets.

  3. 1:52
    APC Releases Peptide Policy Resources

    APC publishes a one-stop guide on peptide regulation, offering recommendations and background for safer compounding practices.

  4. 2:49
    California Pharmacy Fee Increase Proposal

    California proposes steep fee hikes for out-of-state compounding pharmacies, potentially burdening smaller operations.

  5. 3:38
    Deep Dive: APC’s Guardrails for Peptide Compounding

    APC outlines a middle‑ground framework of guardrails to allow responsible peptide compounding while ensuring safety.

  6. 12:05
    API Quality and Repackaging Strategy

    Discussion on ensuring peptide API quality through FDA‑registered repackagers and relabelers to prevent sub‑standard products.

  7. 29:00
    Patient Disclosure and Adverse Event Reporting

    APC proposes enhanced patient disclosure and a structured adverse event reporting system with contextual data.

  8. 36:26
    Closing Remarks and Future Outlook

    Hosts summarize the guardrails, express optimism for FDA action, and encourage listeners to stay informed.

Highlights

Quotes

  • “We are 100% behind that. Some of the big issues in the compounding world that we've covered here are pretty complex.”
    Unnamed speaker · 1:26
  • “The middle ground, it's a framework of meaningful guardrails.”
    Unnamed speaker · 4:03
  • “FDA registration is absolutely the floor. Registration, all it does is identifies this establishment to the FDA.”
    Unnamed speaker · 13:49
  • “We want this to happen. We want it to be available to patients. We want it to be in the most responsible, high-quality way possible for the durability of this within our industry.”
    Unnamed speaker · 35:11
  • APC 37:05–37:48

About this episode

As always, we have the most interesting (and important) news from the pharmacy compounding world, plus this episode we’ve got a deep dive into a future for peptides that protects patients while giving them access to the medications they want and need. Links from the episodeOverview of the peptides issue (and recommendations): a4pc.org/peptidesOverview of the ADT/DTE issue (and recommendations): a4pc.org/dteAPC letter to California BoP about proposed out-of-state fee changes (1-page PDF): https://fllw.me/3Ued75SWashington Post story on potential (temporary) loosening of peptide regs: https://archive.is/fXroEJoin APC: https://a4pc.org/join

Transcript

0:00
37:56

5,915 words · 4 speakers

Topics

  • FDA
  • CGMP
  • PCCAC
  • California Board of Pharmacy
  • GLP-1
  • USP 797
  • Rollins School of Public Health

Page updated · transcript and summary are machine-generated